At Accolade, we strive to strike a balance between clinical considerations and employee welfare. Most recently, this means potentially addressing the obesity epidemic with a new class of drugs - GLP-1s.

HR leaders and plan sponsors face several questions and unknowns regarding how they will address GLP-1s in their strategic benefit plan offerings. This may be the most important benefit plan change to consider this year: How to prioritize employee health while managing pharmacy spend, defining successful outcomes and having guardrails around who is eligible for coverage.

Obesity is a serious health issue requiring real, tangible support. It's time to move beyond the traditional boundaries of healthcare benefits and create a supportive and inclusive environment for all employees. Join our interactive discussion to learn more about:

• The clinical and financial aspects of GLP-1s
• How to effectively address this pressing issue
• Fostering a culture of health and well-being in our workplaces